Insulet Corp. (PODD) Debt to Assets Ratio: 0.33%
The debt to assets ratio for Insulet Corp. (PODD) is 0.33% as of Thursday, June 25, 2026.
PODD Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.33%
PODD Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 0.33% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.42% |
| Baxter International Inc. (BAX)vs › | $10.87B | 0.50% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 0.43% |
| Henry Schein, Inc. (HSIC)vs › | $9.38B | 0.33% |
| Revvity, Inc. (RVTY)vs › | $11.78B | 0.29% |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 0.02% |
| Solventum Corporation (SOLV)vs › | $13.01B | 0.35% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 0.14% |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | 0.07% |
Leverage Ratios Comparison
Debt/Assets
0.3%
Debt/Equity
0.69
Current Ratio
2.78
Interest Coverage
5.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Insulet Corp. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Insulet Corp. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Insulet Corp. (PODD)?
- The debt to assets ratio for PODD stock is 0.33%.
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy